carbostyril has been researched along with Depressive Disorder, Major in 151 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 39 (25.83) | 29.6817 |
| 2010's | 103 (68.21) | 24.3611 |
| 2020's | 9 (5.96) | 2.80 |
| Authors | Studies |
|---|---|
| Furukawa, Y; Hamza, T; Kasai, K; Obata, S; Oguro, S; Ostinelli, EG | 1 |
| Boucher, M; de Jong-Laird, A; Katzman, MA; MacKenzie, EM; Therrien, F; Wang, F | 1 |
| Carpenter, JS; Crouse, JJ; Garland, A; Hickie, IB; Koethe, D; Leweke, FM; McHugh, C; Nichles, A; Rohleder, C; Scott, EM; Song, YJC; Wilson, C; Zmicerevska, N | 1 |
| Eriksson, H; Meehan, SR; Newcomer, JW; Weiss, C; Zhang, P | 1 |
| Carroll, KJ; Koch, G; Lee, J; Ouyang, J; Zhang, P | 1 |
| Antoun Reyad, A; Girgis, E; Mishriky, R | 1 |
| Baker, RA; Krystal, AD; Lindsten, A; Mittoux, A | 1 |
| Mishra, VC; Swami, MK | 1 |
| Futamura, T; Hirose, T; Kikuchi, T; Maeda, K; McQuade, RD; Suzuki, M | 1 |
| Edinoff, AN; Girma, B; Kaye, AD; Kaye, AJ; Kaye, AM; Kaye, JS; Leethy, KN; Maxey, BS; Mychaskiw, G; Odisho, A; Ren, AL; Urits, I; Viswanath, O; Wu, NW | 1 |
| Aftab, A; Gao, K | 1 |
| Dong, C; Fujita, Y; Futamura, T; Hashimoto, K; Ma, M; Ohgi, Y; Ren, Q; Yang, C | 1 |
| Higashi, K; Ishigooka, J; Iwashita, S; Liew, EL; Tadori, Y | 1 |
| Hobart, M; Nelson, JC; Weiller, E; Weiss, C; Zhang, P | 1 |
| Augustine, C; Carroll, K; Hobart, M; Koch, G; Zhang, P | 1 |
| Augustine, C; Brewer, C; Hefting, N; Hobart, M; Josiassen, MK; McQuade, RD; Sanchez, R; Skuban, A; Zhang, P | 1 |
| Aladeen, T; Capote, H; Lee, Y; McIntyre, RS; Rainka, M; Rong, C; Westphal, E | 1 |
| Burudpakdee, C; Greene, M; Hartry, A; Seetasith, A | 1 |
| Augustine, C; Brewer, C; Hefting, N; Hobart, M; McQuade, RD; Sanchez, R; Skuban, A; Zhang, P | 1 |
| Baker, RA; Duffy, RA; Gwin, KK; McQuade, RD; Weiller, E; Weiss, C; Zhang, P | 1 |
| Hefting, N; Hobart, M; Lepola, U; Zhang, D | 1 |
| Bauer, M; Hefting, N; Hobart, M; Josiassen, MK; Lindsten, A | 1 |
| Eriksson, H; Hobart, M; Meehan, SR; Weiss, C; Zhang, P | 1 |
| Broder, MS; Chang, E; Greene, M; Hartry, A; Yan, T; Yermilov, I | 1 |
| Brown, ES; Escalante, C; Holmes, T; Ivleva, E; Khaleghi, N; Mason, BL; Nakamura, A; Van Enkevort, E | 1 |
| Citrome, LL; Manning, JS; McIntosh, D; McIntyre, RS | 1 |
| Iwata, N; Kishi, T; Matsuda, Y; Mishima, K; Nomura, I; Sakuma, K | 1 |
| Begley, AE; Blumberger, D; Butters, M; Dew, MA; Joel, I; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF | 1 |
| Cassiello, C; Dording, C; Fava, M; King, F; Mischoulon, D; Pencina, M | 1 |
| Cho, SJ; Choi, JH; Hahn, SW; Han, C; Jeon, HJ; Jon, DI; Jun, TY; Kim, SG; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Park, EJ; Seo, HJ | 1 |
| Higuchi, T; Ishigooka, J; Kamijima, K; Kanba, S; Kinoshita, T; Koyama, T; Ohmori, T; Ozaki, N | 1 |
| Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Wang, SM | 1 |
| Han, C; Jeon, HJ; Kim, W; Kwak, KP; Lee, BC; Pae, CU; Seo, HJ; Wang, SM | 1 |
| Chibnall, JT; Conway, CR; Cornell, ME; Cumming, P; Gangwani, S; Gebara, MA; McConathy, JE; Mintun, MA; Perantie, DC; Price, JL; Sheline, YI | 1 |
| Begley, A; Butters, MA; Koenig, AM; Ogbagaber, S; Reynolds, CF; Wahed, AS | 1 |
| Baker, RA; Berman, RM; Eudicone, JM; Laubmeier, KK; Marcus, RN; McQuade, RD; Nelson, JC; Rahman, Z; Sheehan, JJ | 1 |
| Berman, RM; Hatch, A; Largay, K; Marler, SV; Nelson, JC; Sheehan, JJ; Stewart, TD | 1 |
| Hu, JY; Huang, A; Liu, YY; Liu, ZL; Wang, LM; Wen, XJ | 1 |
| Philip, NS | 1 |
| Higuchi, T; Kamijima, K; Kato, M; Ono, H; Otsubo, T; Ozaki, N | 1 |
| Makkos, Z | 1 |
| Baker, RA; Berman, RM; Cain, ZJ; Clayton, AH; Forbes, RA; Marcus, R; Marler, SV; Sheehan, JJ; Thase, ME | 1 |
| Sharma, V; Sommerdyk, C; Xie, B | 1 |
| Baker, RA; Dunlop, BW; Eudicone, JM; McCabe, B; Sheehan, JJ | 1 |
| Chiou, CC; Lane, HY; Lin, CY; Tsai, GE; Wang, HS; Wu, VY; Wu, YH | 1 |
| Howland, RH | 1 |
| Huh, L; Lee, BJ | 1 |
| Bond, M; Darwish, M; Hellriegel, ET; Robertson, P; Yang, R | 1 |
| Citrome, L | 4 |
| Augustine, C; Carson, WH; Eriksson, H; Hobart, M; McQuade, RD; Nyilas, M; Sanchez, R; Skuban, A; Thase, ME; Youakim, JM; Zhang, P | 1 |
| Carson, WH; Eriksson, H; Hobart, M; McQuade, RD; Nyilas, M; Sanchez, R; Skuban, A; Thase, ME; Youakim, JM; Zhang, P | 1 |
| McKeage, K | 1 |
| Stahl, SM | 1 |
| McIntyre, RS; Weiller, E; Weiss, C; Zhang, P | 1 |
| Bruijnzeel, D; Tandon, R | 1 |
| Baker, RA; Ota, A; Perry, P; Sheehan, DV; Tsuneyoshi, K; Weiller, E; Weisler, RH | 1 |
| Baker, RA; Davidsen, CK; Fava, M; Ménard, F | 1 |
| Aigbogun, MS; Duffy, R; Hartry, A; Kamat, SA; Legacy, S; Sussman, M; Yu, J | 1 |
| Baker, RA; Davis, LL; Ota, A; Perry, P; Tsuneyoshi, K; Weiller, E | 1 |
| Baker, RA; Fava, M; Matsushima, Y; Okame, T; Perry, P; Weiller, E | 1 |
| Beyer, JL; Weisler, RH | 1 |
| Baker, RA; Krystal, AD; Meisels, P; Mittoux, A | 1 |
| Han, C; Jeon, SW; Ko, YH; Masand, PS; Pae, CU; Patkar, AA; Yoon, S | 1 |
| Dong, C; Futamura, T; Hashimoto, K; Ma, M; Ohgi, Y; Ren, Q; Yang, C; Yao, W; Zhang, JC | 1 |
| Fava, M; Weiller, E; Weiss, C; Zhang, P | 1 |
| Gallipani, A; Markovic, M; Maroney, M; Patel, KH | 1 |
| Karakatsanis, NA; Karapoulios, E; Kouzoupis, AV; Masdrakis, VG; Oulis, P; Soldatos, CR; Zervas, IM | 1 |
| Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
| Lyseng-Williamson, KA; Scott, LJ; Weber, J | 1 |
| Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K | 1 |
| Khan, A | 1 |
| Ammerman, DK; Coley, KC; Fabian, TJ; Ganguli, R; Kim, E; Kim, MS; Saul, MI; Scipio, TM; Whitehead, R | 1 |
| Mathew, SJ | 1 |
| Denninger, JW; Dording, C; Fava, M; Hilliker, S; Homberger, C; Matthews, JD; Park, L; Rooney, K; Siefert, C; Sklarsky, K; van Nieuwenhuizen, AO | 1 |
| Carroll, BJ | 1 |
| Tsai, AC | 1 |
| Kyomen, HH; Whitfield, TH | 1 |
| Berman, RM; Carlson, BX; Fava, M; Marcus, RN; Nelson, CJ; Pikalov, A; Qi, Y; Thase, ME; Tran, QV; Trivedi, MH; Yang, H | 1 |
| Butters, MA; Dew, MA; Driscoll, HC; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Corey-Lisle, PK; Guo, Z; Kim, E; Lennox, RD; Pikalov, A; Trivedi, MH | 1 |
| Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM | 1 |
| Adson, D; Berman, RM; Carson, WH; Fava, M; Hazel, J; Marcus, RN; McQuade, RD; Swanink, R; Taylor, L; Thase, ME; Trivedi, MH | 1 |
| Preskorn, SH | 1 |
| Baker, RA; Berman, RM; Fava, M; Marcus, RN; Pikalov, A; Thase, ME; Tran, QV; Wisniewski, SR; Yang, H | 1 |
| Baker, RA; Berman, RM; Carlson, BX; Eudicone, JM; Mankoski, R; Nelson, JC; Pikalov, A; Tran, QV | 1 |
| Pae, CU | 1 |
| Carlson, BX; Chen, CC; Guo, Z; Kan, HJ; Kim, E; Pikalov, A; Tran, QV; Wisniewski, SR | 1 |
| Ansseau, M; Pitchot, W | 1 |
| Radics, J | 1 |
| Lai, CH | 3 |
| Kitamura, H; Someya, T; Yokoyama, Y | 1 |
| Berman, RM; Carlson, BX; Eudicone, JM; Marchant, BK; Marcus, RN; Martin, ML; Pikalov, A; Reimherr, FW; Tran, QV | 1 |
| Tényi, T; Vörös, V | 1 |
| Berman, RM; Carlson, BX; Eudicone, JM; Khan, A; Pikalov, A; Tran, QV; Trivedi, MH; Weisler, RH; Yang, H | 1 |
| Andersson, C; Berman, RM; Carlson, BX; Eudicone, JM; Forbes, RA; Nelson, JC; Steffens, DC; Tran, QV; Yang, H | 1 |
| Chen, J; Gao, K; Kemp, DE | 1 |
| Guerdjikova, A; Keck, PE; McElroy, SL; Mori, N | 1 |
| Chang, CH; Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
| Ramaswamy, S; Selvaraj, V; Sharma, A; Wilson, D | 1 |
| Depping, AM; Gaudchau, A; Kissling, W; Komossa, K; Leucht, S | 1 |
| Leinonen, E; Valtonen, HM; Viikki, M | 1 |
| Katzman, MA | 1 |
| Blier, P; Blondeau, C | 1 |
| Forbes, A; Pae, CU; Patkar, AA | 1 |
| Leelahanaj, T | 1 |
| Frost, M; Marcus, RM; McQuade, RD; Sanchez, R | 1 |
| Fikretoglu, D; Liu, A; McIntosh, D; Richardson, JD | 1 |
| Catapano, F; Esposito, G; Fabrazzo, M; Maj, M; Monteleone, P; Perris, F | 1 |
| Bagalman, E; Carls, GS; Curkendall, SM; Forbes, RA; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME | 1 |
| Jang, FL; Lin, CH; Lin, SH | 1 |
| Fava, M; Hsieh, WH; Levy, M; Mischoulon, D; Papakostas, GI; Pencina, MJ; Pet, LR; Pollack, MH; Ward, S; Witte, J | 1 |
| Dalton, ED; Dording, CM; Fava, M; Mischoulon, D; Pencina, MJ | 1 |
| Chen, SJ; Chen, ST; Hsiao, YL; Shen, TW | 1 |
| Baker, RA; Berman, RM; Camacho, TA; Chambers, JS; Eudicone, JM; Forbes, RA; Muzina, DJ | 1 |
| Tomba, E | 1 |
| Bou Khalil, R; Dahdah, P; Kahn, DA; Richa, S | 1 |
| Fava, M; Flynn, M; Harper, L; Iosifescu, D; Levy, M; Mischoulon, D; Pencina, M; Pollack, M; Rickels, K; Witte, J | 1 |
| Baker, RA; Bellocchio, EE; Berman, RM; Eudicone, JM; Marcus, RN; McQuade, RD; Nelson, JC; Rollin, LM; Thase, ME | 1 |
| Baker, RA; Forbes, RA; Jing, Y; Oster, G; Papakostas, GI; Taneja, C | 1 |
| Lin, CC; Lin, HY; Liu, CC | 1 |
| Cho, AR; Kang, WS; Park, JK | 1 |
| Forbes, RA; Guo, Z; Hebden, T; Jing, Y; Kalsekar, I; Thase, ME | 1 |
| Choi, JE; Han, DH; Kim, SM; Min, KJ; Renshaw, PF | 1 |
| Doros, G; Fava, M; Meisner, A; Pencina, M; Rybin, D | 1 |
| Hellerstein, DJ | 1 |
| Malik, AR; Ravasia, S | 1 |
| Baldessarini, RJ; Centorrino, F; Cimbolli, P; Cincotta, SL; Fogarty, KV; Salvatore, P; Sani, G; Thompson, TA | 1 |
| Baldessarini, RJ; Grant, MJ | 1 |
| Nemeroff, CB; Simon, JS | 1 |
| Alpert, JE; Burns, AM; Fava, M; Kinrys, G; Nierenberg, AA; Papakostas, GI; Petersen, TJ; Worthington, JJ | 1 |
| Sharma, A; Sorrell, JH | 1 |
| Maytal, G; Ostacher, M; Stern, TA | 1 |
| Jun, TY; Lee, C; Masand, PS; Pae, CU; Paik, IH; Patkar, AA | 1 |
| Fiedler, U; Wolf, J | 1 |
| Carroll, BT; Goforth, HW | 1 |
| Baghai, TC; Born, C; Eser, D; Häfner, S; Hecht, S; Hermisson, I; Nothdurfter, C; Rupprecht, R; Schüle, C | 1 |
| Berman, RM; Carson, WH; Corey-Lisle, PK; Khan, A; Marcus, RN; McQuade, RD; Swanink, R | 1 |
| Burrows, G; Jefferys, D | 1 |
| Arnold, KK; Yager, J | 1 |
| Chou, YH; Su, TP; Yang, KC | 1 |
| Papakostas, GI; Shelton, RC | 1 |
| Bowden, CL; Carson, WH; Jonas, A; Khan, A; Marcus, RN; McQuade, RD; Owen, R; Thase, ME; Wu, X | 1 |
| Chriki, LS; Dunn, RT; Filkowski, MM; Ghaemi, SN; Stan, VA | 1 |
| Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH | 1 |
31 review(s) available for carbostyril and Depressive Disorder, Major
| Article | Year |
|---|---|
Optimal dose of brexpiprazole for augmentation therapy of antidepressant-refractory depression: A systematic review and dose-effect meta-analysis.
Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Male; Quinolones; Randomized Controlled Trials as Topic; Reproducibility of Results; Thiophenes | 2022 |
Efficacy and safety of brexpiprazole in acute management of psychiatric disorders: a meta-analysis of randomized controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Schizophrenia; Thiophenes; Treatment Outcome | 2020 |
Discovery research and development history of the dopamine D
Topics: Aripiprazole; Depressive Disorder, Major; Dopamine; Dopamine Agonists; Humans; Quinolones; Research; Thiophenes; United States | 2021 |
Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
Topics: Antipsychotic Agents; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes | 2021 |
The preclinical discovery and development of brexpiprazole for the treatment of major depressive disorder.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Drug Evaluation, Preclinical; Drug Therapy, Combination; Humans; Quinolones; Thiophenes | 2017 |
Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale.
Topics: Antidepressive Agents; Depressive Disorder, Major; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Humans; Prospective Studies; Quinolones; Randomized Controlled Trials as Topic; Serotonin Agents; Single-Blind Method; Thiophenes | 2019 |
Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Humans; Outcome Assessment, Health Care; Quinolones; Randomized Controlled Trials as Topic; Serotonin Agents; Thiophenes | 2019 |
Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chemotherapy, Adjuvant; Depressive Disorder, Major; Dibenzothiazepines; Double-Blind Method; Drug Synergism; Humans; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Risperidone; Treatment Outcome; Young Adult | 2014 |
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel
Topics: Antidepressive Agents; Antipsychotic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Schizophrenia; Thiophenes | 2015 |
Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Topics: Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptors, Dopamine D2; Schizophrenia; Thiophenes | 2015 |
Brexpiprazole (Rexulti) for schizophrenia and depression.
Topics: Animals; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Serotonin Agents; Thiophenes | 2015 |
Adjunctive Brexpiprazole: A Review in Major Depressive Disorder.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Quinolones; Thiophenes | 2016 |
Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression.
Topics: Animals; Depressive Disorder, Major; Humans; Quinolones; Schizophrenia; Thiophenes | 2016 |
Adjunctive Brexpiprazole as a Novel Effective Strategy for Treating Major Depressive Disorder: A Systematic Review and Meta-Analysis.
Topics: Depressive Disorder, Major; Humans; Quinolones; Serotonin Agents; Thiophenes | 2017 |
Brexpiprazole.
Topics: Antidepressive Agents; Antipsychotic Agents; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Thiophenes; Weight Gain | 2017 |
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome | 2008 |
Aripiprazole: in major depressive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Disability Evaluation; Drug Tolerance; Humans; Piperazines; Quinolones | 2008 |
Current evidence for aripiprazole as augmentation therapy in major depressive disorder.
Topics: Antipsychotic Agents; Aripiprazole; Chemotherapy, Adjuvant; Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Evidence-Based Medicine; Humans; Piperazines; Quinolones; Treatment Outcome | 2008 |
Treatment-resistant depression: recent developments and future directions.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Combined Modality Therapy; Deep Brain Stimulation; Depressive Disorder, Major; Drug Resistance; Electroconvulsive Therapy; Humans; Piperazines; Prognosis; Quinolones; Tetrahydrofolates; Transcranial Magnetic Stimulation; Treatment Outcome; Vagus Nerve Stimulation | 2008 |
Treatment options for the patient who does not respond well to initial antidepressant therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Drug Approval; Drug Resistance; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Piperazines; Psychotropic Drugs; Quinolones; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Vagus Nerve Stimulation | 2009 |
Metabolic assessment of aripiprazole as adjunctive therapy in major depressive disorder: a pooled analysis of 2 studies.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Biomarkers; Blood Glucose; Body Mass Index; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Lipid Metabolism; Lipids; Logistic Models; Male; Metabolic Diseases; Middle Aged; Multicenter Studies as Topic; Obesity; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult | 2009 |
Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Biostatistics; Clinical Trials as Topic; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Therapy, Combination; Epidemiologic Measurements; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones | 2010 |
Second-generation antipsychotics in major depressive disorder: update and clinical perspective.
Topics: Adult; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Sulpiride | 2011 |
Therapeutic potential of new second generation antipsychotics for major depressive disorder.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Mianserin; Mirtazapine; Piperazines; Quinolones; Randomized Controlled Trials as Topic | 2010 |
Second-generation antipsychotics for major depressive disorder and dysthymia.
Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dysthymic Disorder; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Sulpiride | 2010 |
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Anxiety Disorders; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones | 2011 |
Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2011 |
Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.
Topics: Animals; Aripiprazole; Clinical Trials as Topic; Depressive Disorder, Major; Drug Interactions; Humans; Piperazines; Quinolones | 2011 |
Lycanthropy as a culture-bound syndrome: a case report and review of the literature.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Behavior Control; Citalopram; Cultural Characteristics; Culture; Delusions; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethnopsychology; Female; Humans; Lebanon; Middle Aged; Mythology; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2012 |
Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Topics: Adult; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Evidence-Based Medicine; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Remission Induction; Time Factors; Treatment Outcome | 2012 |
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Fluoxetine; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Serotonin 5-HT2 Receptor Antagonists; Thiazoles; Trazodone; Triazoles | 2008 |
48 trial(s) available for carbostyril and Depressive Disorder, Major
| Article | Year |
|---|---|
Efficacy of adjunctive brexpiprazole on symptom clusters of major depressive disorder: A post hoc analysis of four clinical studies.
Topics: Adult; Anhedonia; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fatigue; Humans; Quinolones; Syndrome; Thiophenes; Treatment Outcome | 2022 |
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole: Pooled Analysis of Phase 3 Clinical Studies.
Topics: Adult; Antidepressive Agents; Blood Glucose; Body Weight; Cholesterol; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Middle Aged; Quinolones; Thiophenes; Triglycerides | 2019 |
Pharmacokinetics and Safety of Brexpiprazole Following Multiple-Dose Administration to Japanese Patients With Schizophrenia.
Topics: Antipsychotic Agents; Area Under Curve; Asian People; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Quinolones; Schizophrenia; Thiophenes | 2018 |
Efficacy of adjunctive brexpiprazole on the core symptoms of major depressive disorder: A post hoc analysis of two pooled clinical studies.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome | 2018 |
A case study in identifying targeted patients population in major depressive disorder by enhanced enrichment design.
Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Delivery Systems; Humans; Patient Selection; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome | 2018 |
Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Humans; Male; Middle Aged; Prospective Studies; Psychomotor Agitation; Quetiapine Fumarate; Quinolones; Thiophenes; Treatment Outcome | 2018 |
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Fixed-Dose Brexpiprazole 2 mg/d as Adjunctive Treatment of Adults With Major Depressive Disorder.
Topics: Adult; Antidepressive Agents; Anxiety; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Psychiatric Status Rating Scales; Quinolones; Thiophenes; Treatment Outcome; Young Adult | 2018 |
A randomised, placebo-controlled 24-week study evaluating adjunctive brexpiprazole in patients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Quinolones; Serotonin Agents; Thiophenes; Young Adult | 2019 |
Dynamic prediction of treatment response in late-life depression.
Topics: Age of Onset; Aged; Aged, 80 and over; Aripiprazole; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Piperazines; Predictive Value of Tests; Psychiatric Status Rating Scales; Quinolones; Remission Induction; Severity of Illness Index; Signal Detection, Psychological; Symptom Assessment; Treatment Outcome; Venlafaxine Hydrochloride | 2014 |
The effects of aripiprazole on the subscales of the Kellner Symptom Questionnaire in treatment resistant depression.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Hostility; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Young Adult | 2013 |
Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: a 12-week prospective open-label multicentre study.
Topics: Adult; Antidepressive Agents; Aripiprazole; Chronic Disease; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Secondary Prevention; Treatment Outcome | 2013 |
Aripiprazole augmentation to antidepressant therapy in Japanese patients with major depressive disorder: a randomized, double-blind, placebo-controlled study (ADMIRE study).
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Asian People; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Time Factors; Treatment Outcome | 2013 |
Aripiprazole augmentation for major depressive disorder: dosing patterns in a naturalistic treatment setting.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2014 |
Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants: a multi-center, naturalistic study.
Topics: Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Substitution; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones | 2014 |
Antidepressant response to aripiprazole augmentation associated with enhanced FDOPA utilization in striatum: a preliminary PET study.
Topics: Adult; Animals; Antidepressive Agents; Aripiprazole; Caudate Nucleus; Citalopram; Corpus Striatum; Depressive Disorder, Major; Dihydroxyphenylalanine; Dopamine; Dopamine Agonists; Drug Synergism; Female; Humans; Magnetic Resonance Imaging; Male; Piperazines; Positron-Emission Tomography; Quinolones; Sample Size; Single-Blind Method; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2014 |
Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Odds Ratio; Piperazines; Psychomotor Agitation; Quinolones; Severity of Illness Index | 2014 |
Efficacy of aripiprazole augmentation in Japanese patients with major depressive disorder: a subgroup analysis and Montgomery-Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression item analyses of the Aripiprazole Depression Multicenter
Topics: Adrenergic Uptake Inhibitors; Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Japan; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2015 |
Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study.
Topics: Adult; Antidepressive Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Norepinephrine; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Serotonin; Sexual Behavior; Treatment Outcome | 2014 |
Evaluation of Potential Pharmacokinetic Drug-Drug Interaction between Armodafinil and Aripiprazole in Healthy Adults.
Topics: Adolescent; Adult; Antipsychotic Agents; Area Under Curve; Aripiprazole; Benzhydryl Compounds; Cytochrome P-450 CYP3A Inducers; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Middle Aged; Modafinil; Piperazines; Quinolones; Wakefulness-Promoting Agents; Young Adult | 2015 |
Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Thiophenes; Treatment Outcome; Young Adult | 2015 |
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Thiophenes; Treatment Outcome; Young Adult | 2015 |
Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Depression; Depressive Disorder, Major; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Psychomotor Agitation; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome | 2016 |
Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment.
Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Employment; Female; Follow-Up Studies; Humans; Male; Psychiatric Status Rating Scales; Quinolones; Students; Thiophenes; Treatment Outcome; Young Adult | 2016 |
Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Irritable Mood; Male; Middle Aged; Outcome Assessment, Health Care; Quinolones; Serotonin Agents; Thiophenes | 2016 |
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study.
Topics: Anxiety; Depressive Disorder, Major; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Least-Squares Analysis; Male; Middle Aged; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinolones; Serotonin Agents; Thiophenes; Treatment Outcome | 2016 |
Switching from Inadequate Adjunctive or Combination Treatment Options to Brexpiprazole Adjunctive to Antidepressant: An Open-Label Study on the Effects on Depressive Symptoms and Cognitive and Physical Functioning.
Topics: Antidepressive Agents; Aripiprazole; Bupropion; Central Nervous System Stimulants; Cognition; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Therapy, Combination; Female; Humans; Impulsive Behavior; Male; Middle Aged; Psychiatric Status Rating Scales; Quetiapine Fumarate; Quinolones; Sleep; Thiophenes; Treatment Outcome | 2017 |
Effects of Adjunctive Brexpiprazole on Sleep Disturbances in Patients With Major Depressive Disorder: An Open-Label, Flexible-Dose, Exploratory Study.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dopamine Agonists; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Quinolones; Serotonin Agents; Sleep Wake Disorders; Thiophenes; Treatment Outcome | 2016 |
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Piperazines; Quinolones; Sertraline; Treatment Outcome; United States; Venlafaxine Hydrochloride; Young Adult | 2010 |
Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Body Weight; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Personality Inventory; Piperazines; Quinolones; Treatment Outcome | 2008 |
Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duloxetine Hydrochloride; Feasibility Studies; Female; Humans; Male; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Thiophenes; Venlafaxine Hydrochloride | 2009 |
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome | 2009 |
Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Failure; Young Adult | 2009 |
Effects of aripiprazole adjunctive to standard antidepressant treatment on the core symptoms of depression: a post-hoc, pooled analysis of two large, placebo-controlled studies.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Cyclohexanols; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Venlafaxine Hydrochloride | 2010 |
A pooled MADRS/IDS cross-correlation analysis: clinician and patient self-report assessment of improvement in core depressive symptoms with adjunctive aripiprazole.
Topics: Adolescent; Adult; Aged; Aripiprazole; Cross-Sectional Studies; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Patient Satisfaction; Physician's Role; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome; Young Adult | 2010 |
Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder.
Topics: Adult; Age Factors; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Suicidal Ideation; Time Factors; Young Adult | 2011 |
Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Young Adult | 2011 |
The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Asian People; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Drug Therapy, Combination; Humans; Models, Economic; Outpatients; Piperazines; Quality-Adjusted Life Years; Quinolones; Thailand; Treatment Outcome | 2010 |
Aripiprazole augmentation strategy in clomipramine-resistant depressive patients: an open preliminary study.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clomipramine; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Sertraline; Treatment Outcome; Young Adult | 2011 |
Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2012 |
A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Constipation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Placebos; Quinolones; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; United States; Weight Gain; Young Adult | 2012 |
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
Topics: Adult; Alcohol Deterrents; Alcohol Drinking; Alcoholism; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Functional Neuroimaging; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurons; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Quinolones; Selective Serotonin Reuptake Inhibitors | 2013 |
Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2005 |
Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study.
Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Neurologic Examination; Personality Inventory; Piperazines; Quinolones | 2007 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Severity of Illness Index; Treatment Outcome | 2007 |
Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Endpoint Determination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones | 2008 |
A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression.
Topics: Acute Disease; Adolescent; Adult; Akathisia, Drug-Induced; Ambulatory Care; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Lorazepam; Male; Middle Aged; Nausea; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2008 |
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment | 2008 |
72 other study(ies) available for carbostyril and Depressive Disorder, Major
| Article | Year |
|---|---|
Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial.
Topics: Adolescent; Depressive Disorder, Major; Humans; Quinolones; Sleep; Sleep Wake Disorders; Thiophenes; Young Adult | 2022 |
Comparisons of global tests on intersection hypotheses and their application in matched parallel gatekeeping procedures.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Computer Simulation; Data Interpretation, Statistical; Depressive Disorder, Major; Dose-Response Relationship, Drug; Endpoint Determination; Humans; Models, Statistical; Quinolones; Randomized Controlled Trials as Topic; Research Design; Thiophenes; Treatment Outcome | 2020 |
Chronobiologic parameter changes in patients with major depressive disorder and sleep disturbance treated with adjunctive brexpiprazole: An open-label, flexible-dose, exploratory substudy.
Topics: Circadian Rhythm; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Melatonin; Quinolones; Sleep; Thiophenes; Treatment Outcome | 2021 |
Interest-Activity Dimension and Response to Aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Humans; Quinolones | 2020 |
Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.
Topics: Administration, Oral; Amino Acids; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Fluoxetine; Ketamine; Male; Mice; Mice, Inbred C57BL; Quinolones; Receptors, N-Methyl-D-Aspartate; Thiophenes | 2017 |
The use of brexpiprazole amongst individuals with insufficient outcomes with aripiprazole or bupropion: A case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; New York; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.
Topics: Adult; Age Factors; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Female; Health Expenditures; Health Resources; Health Services; Humans; Insurance Claim Review; Lurasidone Hydrochloride; Male; Middle Aged; Models, Econometric; Quetiapine Fumarate; Quinolones; Residence Characteristics; Retrospective Studies; Sex Factors; Socioeconomic Factors; Thiophenes; Time-to-Treatment | 2018 |
The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Longitudinal Studies; Male; Meta-Analysis as Topic; Middle Aged; Quinolones; Randomized Controlled Trials as Topic; Schizophrenia; Thiophenes; Weight Gain | 2018 |
Adjunctive brexpiprazole for elderly patients with major depressive disorder: An open-label, long-term safety and tolerability study.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Antidepressive Agents; Chemotherapy, Adjuvant; Depressive Disorder, Major; Europe; Fatigue; Female; Humans; Male; Quality of Life; Quinolones; Social Participation; Thiophenes; United States | 2018 |
Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Depressive Disorder, Major; Emergency Service, Hospital; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Quetiapine Fumarate; Quinolones; Thiophenes; United States; Young Adult | 2019 |
A pilot study of brexpiprazole for bipolar depression.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Cognition; Depressive Disorder, Major; Female; Humans; Irritable Mood; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Quinolones; Thiophenes; Treatment Outcome; Young Adult | 2019 |
Activating and Sedating Properties of Medications Used for the Treatment of Major Depressive Disorder and Their Effect on Patient Functioning.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Aripiprazole; Arousal; Comorbidity; Delayed-Action Preparations; Depressive Disorder, Major; Drug Approval; Drug Therapy, Combination; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Practice Patterns, Physicians'; Quality of Life; Quetiapine Fumarate; Quinolones; Sleep Initiation and Maintenance Disorders; Thiophenes | 2019 |
Response to antidepressant medications in late-life depression across the spectrum of cognitive functioning.
Topics: Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Citalopram; Cognitive Dysfunction; Cyclohexanols; Dementia; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Male; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Recurrence; Selective Serotonin Reuptake Inhibitors; Thiophenes; Time Factors; Venlafaxine Hydrochloride | 2014 |
Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Time Factors | 2014 |
An aripiprazole discontinuation syndrome.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome | 2013 |
[Antipsychotics -- do they exist?].
Topics: Adaptation, Psychological; Affect; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Corpus Striatum; Depressive Disorder, Major; Dopamine; Dopamine Agents; Humans; Obsessive-Compulsive Disorder; Off-Label Use; Piperazines; Psychotic Disorders; Quinolones; Risperidone; Stress, Psychological; Thinking | 2014 |
Aripiprazole augmentation of antidepressants for postpartum depression: a preliminary report.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depression, Postpartum; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Piperazines; Psychiatric Status Rating Scales; Quinolones; Treatment Outcome | 2015 |
How well do clinicians and patients agree on depression treatment outcomes? Implications for personalized medicine.
Topics: Adult; Antidepressive Agents; Anxiety; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Piperazines; Precision Medicine; Prognosis; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Self Report; Treatment Outcome | 2014 |
Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dibenzothiazepines; Drug Synergism; Drug Therapy, Combination; Emergency Service, Hospital; Female; Hospitalization; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Taiwan; Treatment Outcome | 2014 |
Brexpiprazole: another multipurpose antipsychotic drug?
Topics: Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Depressive Disorder, Major; Humans; Psychomotor Agitation; Quinolones; Schizophrenia; Stress Disorders, Post-Traumatic; Thiophenes | 2015 |
Efficacy of aripiprazole in antidepressants-induced tardive dystonia and tardive dyskinesia: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Dystonic Disorders; Female; Humans; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2015 |
The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dopamine Agonists; Drug Administration Schedule; Drug Interactions; Humans; Piperazines; Quinolones; Schizophrenia; Thiophenes | 2015 |
Mechanism of action of brexpiprazole: comparison with aripiprazole.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dopamine Agonists; Humans; Quinolones; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-1; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin 5-HT2 Receptor Antagonists; Serotonin Agents; Thiophenes | 2016 |
Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Depressive Disorder, Major; Disorders of Excessive Somnolence; Drug Costs; Drug Therapy, Combination; Fatigue; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Olanzapine; Patient Selection; Quetiapine Fumarate; Quinolones; Serotonin Agents; Thiophenes; Weight Gain; Young Adult | 2017 |
Adjunctive brexpiprazole for the treatment of major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Chemotherapy, Adjuvant; Depressive Disorder, Major; Dopamine; Humans; Quinolones; Randomized Controlled Trials as Topic; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT1; Serotonin 5-HT1 Receptor Agonists; Thiophenes; Treatment Outcome | 2016 |
Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling.
Topics: Animals; Antidepressive Agents; Azepines; Behavior, Animal; Benzamides; Brain-Derived Neurotrophic Factor; Dendritic Spines; Depressive Disorder, Major; Disease Models, Animal; Drug Therapy, Combination; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Phenotype; Quinolones; Receptor, trkB; Selective Serotonin Reuptake Inhibitors; Signal Transduction; Thiophenes | 2016 |
Efficacy of Brexpiprazole as Adjunctive Treatment in Major Depressive Disorder With Irritability: Post Hoc Analysis of 2 Pivotal Clinical Studies.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Irritable Mood; Middle Aged; Quinolones; Thiophenes | 2017 |
The safety of the electroconvulsive therapy-aripiprazole combination: four case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Inpatients; Middle Aged; Piperazines; Quinolones; Safety; Schizophrenia | 2008 |
Predictors of aripiprazole treatment continuation in hospitalized patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Child; Child, Preschool; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Patient Discharge; Piperazines; Psychotic Disorders; Quinolones; Retrospective Studies; Treatment Outcome | 2008 |
An open study of aripiprazole and escitalopram for psychotic major depressive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Citalopram; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Selective Serotonin Reuptake Inhibitors | 2009 |
Aripiprazole in refractory depression?
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2009 |
Unclear clinical significance of findings in adjunctive aripiprazole for major depressive disorder: comments on article by Marcus et al.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Humans; Piperazines; Quinolones; Treatment Outcome | 2009 |
Psychosis in the elderly.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Combined Modality Therapy; Comorbidity; Cyclohexanols; Delirium; Depressive Disorder, Major; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Memantine; Nootropic Agents; Piperazines; Psychotherapy; Psychotic Disorders; Quinolones; Risk Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2009 |
Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
Topics: Adult; Algorithms; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Data Interpretation, Statistical; Depressive Disorder, Major; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Models, Statistical; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Socioeconomic Factors; Treatment Failure | 2009 |
Potential utility of aripiprazole monotherapy for the treatment of major depressive disorder comorbid with obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Treatment Outcome | 2009 |
Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multicenter Studies as Topic; Odds Ratio; Piperazines; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2009 |
Aripiprazole, hypertension, and confusion.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Confusion; Depressive Disorder, Major; Female; Humans; Hypertension; Piperazines; Quinolones | 2010 |
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses | 2010 |
Aripiprazole-induced gray matter growth in a patient with major depressive disorder with panic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brain Mapping; Comorbidity; Depressive Disorder, Major; Female; Humans; Magnetic Resonance Imaging; Organ Size; Panic Disorder; Piperazines; Quinolones; Receptors, Serotonin | 2010 |
Aripiprazole monotherapy in a patient with major depressive disorder.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Piperazines; Quinolones; Treatment Outcome | 2010 |
[Use of aripiprazole in the treatment of catatonia].
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Catatonia; Depressive Disorder, Major; Humans; Injections, Intramuscular; Male; Middle Aged; Piperazines; Psychomotor Performance; Quinolones; Schizoid Personality Disorder; Schizophrenia, Catatonic | 2010 |
Aripiprazole-related subcortical growth in a patient with major depressive disorder and panic disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Depressive Disorder, Major; Humans; Male; Panic Disorder; Piperazines; Quinolones; Treatment Outcome | 2010 |
Aripiprazole augmentation induced hypertension in major depressive disorder: a case report.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Synergism; Duloxetine Hydrochloride; Female; Humans; Hypertension; Middle Aged; Piperazines; Quinolones; Thiophenes | 2011 |
New-onset psychosis and emergence of suicidal ideation with aripiprazole.
Topics: Antidepressive Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Middle Aged; Piperazines; Psychoses, Substance-Induced; Quinolones; Suicidal Ideation | 2010 |
Three cases of hypomania and one case of mania during aripiprazole treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Young Adult | 2011 |
Aripiprazole adjunctive to antidepressant therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones | 2011 |
Aripiprazole augmentation in the treatment of military-related PTSD with major depression: a retrospective chart review.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotropic Drugs; Quinolones; Retrospective Studies; Stress Disorders, Post-Traumatic; Veterans | 2011 |
Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Data Interpretation, Statistical; Databases, Factual; Depressive Disorder, Major; Dibenzothiazepines; Drug Costs; Drug Therapy, Combination; Drug Utilization Review; Female; Health Expenditures; Humans; Insurance Claim Review; Male; Middle Aged; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Young Adult | 2011 |
Adjunctive antipsychotics for major depression.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Therapy, Combination; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; United States; United States Food and Drug Administration | 2011 |
Comparison of academic and nonacademic sites in multi-center clinical trials.
Topics: Academic Medical Centers; Academies and Institutes; Adult; Antipsychotic Agents; Aripiprazole; Boston; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Hospitals, General; Humans; Interview, Psychological; Male; Middle Aged; Multicenter Studies as Topic; Patient Dropouts; Patient Selection; Piperazines; Quinolones; Randomized Controlled Trials as Topic; Risk Factors; Young Adult | 2012 |
The effectiveness and safety of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder: a prospective, open-label trial.
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cross-Cultural Comparison; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Prospective Studies; Quinolones; Thailand; Young Adult | 2012 |
Adjunctive aripiprazole for depression: predictive value of early assessment.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Health Status Indicators; Humans; Logistic Models; Models, Psychological; Multivariate Analysis; Piperazines; Predictive Value of Tests; Prospective Studies; Psychometrics; Quinolones; Time Factors | 2011 |
Nowhere patients.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Female; Humans; Male; Models, Statistical; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors | 2012 |
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; Decision Support Techniques; Depressive Disorder, Major; Dibenzothiazepines; Drug Combinations; Drug Costs; Drug Resistance; Fluoxetine; Health Care Costs; Humans; Piperazines; Quetiapine Fumarate; Quinolones | 2012 |
Aripiprazole monotherapy-related gray-matter growth in a patient with first-episode drug-naïve non-psychotic major depressive disorder.
Topics: Aripiprazole; Brain; Depressive Disorder, Major; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Middle Aged; Piperazines; Quinolones | 2012 |
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Piperazines; Quinolones; Recurrence | 2012 |
Aripiprazole for the treatment of involuntary movement symptoms in patients with major depressive disorder.
Topics: Aripiprazole; Depressive Disorder, Major; Dyskinesias; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Treatment Outcome | 2012 |
Dosing patterns of aripiprazole and quetiapine for adjunctive treatment of major depressive disorder (2006-2010).
Topics: Adolescent; Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Cohort Studies; Depressive Disorder, Major; Dibenzothiazepines; Drug Approval; Drug Prescriptions; Drug Therapy, Combination; Drugs, Investigational; Female; Humans; Insurance, Pharmaceutical Services; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Retrospective Studies; Spatio-Temporal Analysis; United States; United States Food and Drug Administration; Young Adult | 2013 |
A repeated measures model for analysis of continuous outcomes in sequential parallel comparison design studies.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computer Simulation; Depressive Disorder, Major; Humans; Linear Models; Piperazines; Placebo Effect; Quinolones; Randomized Controlled Trials as Topic; Research Design | 2013 |
Aripiprazole as an adjunctive treatment for refractory major depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Piperazines; Quinolones | 2004 |
Aripiprazole-induced seizure.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Diagnosis, Differential; Epilepsy, Complex Partial; Humans; Male; Piperazines; Quinolones | 2005 |
Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitalization; Humans; Male; Mathematical Computing; Middle Aged; Obesity; Piperazines; Product Surveillance, Postmarketing; Psychotic Disorders; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2005 |
Possible improvement of neuroleptic-associated tardive dyskinesia during treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Delusions; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Haloperidol; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder.
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Research Design; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome | 2005 |
Aripiprazole-induced parkinsonism.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Humans; Male; Middle Aged; Parkinsonian Disorders; Piperazines; Quinolones | 2006 |
Aripiprazole-related tardive dyskinesia.
Topics: Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Quinolones | 2006 |
Aripiprazole augmentation for treatment of patients with inadequate antidepressants response.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Personality Inventory; Pilot Projects; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2007 |
Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole.
Topics: Adult; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Olanzapine; Piperazines; Quinolones | 2007 |
Aripiprazole augmentation of tranylcypromine in treatment-resistant major depression.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Female; Humans; Middle Aged; Monoamine Oxidase Inhibitors; Piperazines; Quinolones; Tranylcypromine; Treatment Outcome | 2007 |
Reversal of trichotillomania with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Morpholines; Piperazines; Quinolones; Reboxetine; Self Concept; Sertraline; Social Adjustment; Trichotillomania | 2008 |
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule; Drug Therapy, Combination; Ephedrine; Feeding and Eating Disorders; Female; Fluoxetine; Humans; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders | 2007 |
Effectiveness of aripiprazole in treating obsessive compulsive symptoms.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Comorbidity; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |